Discovery Life Sciences SpecimenSeq
Discovery Life Sciences has launched SpecimenSeq, a collection of high-quality, fully consented biospecimens to help researchers identify, develop, and validate new biomarker signatures for precision medicine applications.
SpecimenSeq is composed of matched biospecimen sets including FFPE, double-spun plasma, and buffy coat formats from treatment-naive cancer patients. The biospecimens are fully annotated with clinical data and the FFPE biospecimens specifically include clinically relevant genomic variants from 64 genes. Genomic data for SpecimenSeq are produced using the custom HAD QGEN MultiModal Panel-based DNA and RNA analysis service available exclusively through Discovery's sequencing and bioinformatics laboratory, HudsonAlpha Discovery. This panel service uses Qiagen's QIAseq MultiModal targeted DNA and RNA sequencing chemistry and analysis platform that is also available as a standalone service through HudsonAlpha Discovery with variant allele frequency detection at less than 5 percent.